when science, technology, and money clash
Generally, when skeptics or popular science writers talk about medicine and money, it’s to ward off something one could call an argument ad-shillium, or rejecting scientific studies outright with declarations that anyone who sticks up for doctors and pharmaceutical companies over the hot and trendy snake oil salesperson of the month must be a paid shill. Shilling certainly happens in both the real world and online, but when one’s argument rests in basic science, money is not a topic relevant to the conversation. However, that doesn’t mean that it’s not important when new ideas come along and gain some serious traction. Case in point, Theranos, a company which a lot of people rightly suspect can shake up healthcare in the United States by offering dozens of blood using just a drop of blood at your corner pharmacy, is facing a barrage of questions as to how exactly its tests work and seems to be unwilling to tell anyone about their lab on a chip.
Ordinarily, this is where an experienced skeptic would look for signs of quackery. Useless tests, pseudoscientifc mumbo-jumbo on the website, avoidance of the FDA, and special pleading for the enigmatic technology which offers vague benefits that don’t run afoul of the agency’s rules for the same of pharmaceuticals and medical devices. But that’s not the case with Theranos. In fact, the company recently got a nod from the FDA to continue its work and is seeking approval of its technology and testing methods, and scientists who have tried to parse how it can test for so many things with so little blood say that it’s more than likely upgrading old technology into a new, compact toolkit. There’s no voodoo or snake oil here, just good old fashioned science and faster, better computers and machinery. Furthermore, the fees for each test are posted openly, and they’re a lot less than what’s offered by its competitors, whose pricing is opaque at best.
So if there’s nothing amiss at Theranos, why all the secrecy? Well, after many millions spent on research, development, and testing, the company wants to expand significantly and if it shares how it does what it does with the world, especially if it’s just an overhaul of existing methodology with better machinery, its competitors can quickly catch up and limit its growth. I’m sure it’s also trying to avoid getting patent trolled and bogged down in expensive litigation, more than likely of the frivolous, made to line lawyers’ pockets variety, since there’s no shortage of people with an abandoned medical testing device patent from which a troll can manufacture an infringement or two and file in East Texas. Perhaps this is unfair to scientists, and to some degree patients who may want a second opinion after Theranos’ tests show something alarming, but this is the result of setting up a healthcare system with opaque pricing and strict regulation, and legal minefields in the technology world through easy to obtain and vaguely worded frivolous patents.